Lenz Therapeutics shares rise 2.15% premarket after Lotus Pharmaceuticals reported a 6% revenue increase in the U.S. and Southeast Asia.

Lenz Therapeutics, Inc. rose 2.15% in premarket trading. The company's stock price increase may be attributed to the positive financial performance of Lotus Pharmaceuticals, which reported a new first-half revenue record of NT$9,477 million, driven by sustained growth of lenalidomide in the U.S. and strong performance in Southeast Asian markets.